Tetranectin (4B3) Monoclonal Antibody

$Lane 1: Rat Skin; Lane 2: Human Skin; Probed with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:1000, overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Rat Skin; Lane 2: Human Skin; Probed with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:1000, overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100 in HepG2 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human Liver Cancer tissue incubated with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Liver Cancer tissue incubated with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Kidney tissue incubated with Tetranectin (4B3) Monoclonal Antibody (bsm-54379R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
IHC-P
IF(IHC-P)
IF(ICC)

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-54379R
Product Name	Tetranectin (4B3) Monoclonal Antibody
Applications	WB, IHC-P, IF(IHC-P), IF(ICC)
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Recombinant protein within human Tetranectin aa 100-250.
Clonality	Monoclonal
Clone #	#REF!
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at 4C for up to 2 weeks. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.
Target
Gene ID	7123
Swiss Prot	P05452
Subcellular location	Secreted
Synonyms	Tetranectin; C-type lectin domain family 3 member B; Plasminogen kringle 4-binding protein; TN; CLEC3B; TNA
Background	Tetranectin is a homotrimeric glycoprotein present in plasma and various tissue locations that binds to calcium, heparin, and plasminogen kringle 4. Tetranectin may play a prominent role in tissue remodeling as well as in the regulation of proteolytic processes via its binding and indirect activation of plasminogen. Tetranectin is found in the extracellular matrix (ECM) of certain carcinomas, but is not present in the ECM of normal tissues. Extracellular proteolysis is an important factor in the ability of malignant cells to penetrate normal tissues and metastasize. Decreased plasma tetranectin or increased tetranectin in stroma of cancers correlates with cancer progression and a grim prognosis. Tetranectin may also influence cancer growth by altering activities of plasminogen or the plasminogen fragment, angiostatin which inhibits tumor cell proliferation.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IF(IHC-P)	1:50-200
IF(ICC)	1:50-200